Solid Tumors Clinical Trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 84 clinical trials
A Trial of ZL-1201 in Subjects With Advanced Cancer

First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer

  • 0 views
  • 19 Feb, 2024
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.

  • 0 views
  • 19 Feb, 2024
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.

measurable disease
lenvatinib
karnofsky performance status
ototoxicity
cancer
  • 0 views
  • 19 Feb, 2024
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

  • 0 views
  • 29 Feb, 2024
  • 1 location
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

  • 0 views
  • 29 Feb, 2024
  • 1 location
AMG 510 Ethnic Sensitivity Study (CodeBreak 105).

To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.

  • 0 views
  • 19 Feb, 2024
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions

The main purpose of this study is to evaluate the efficacy and safety of nicotinic acid in solid tumor patients with grade II/III VEGFRi-associated HFSR.

  • 0 views
  • 19 Feb, 2024
SBRT for Breast Cancer Oligometastases

Response and progression for these metastases will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions is used in the RECIST criteria.

breast cancer
bone scan
primary tumor
solid tumor
solid tumors
  • 0 views
  • 19 Feb, 2024
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

hiv related lymphoma
b-cell lymphoma
diffuse large b-cell lymphoma
lenalidomide
gemox
  • 0 views
  • 19 Feb, 2024
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

neuroendocrine carcinoma
solid tumour
squamous cell carcinoma
electrocardiogram
carcinoma lung
  • 0 views
  • 19 Feb, 2024